Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Core Viewpoint - Skye Bioscience, Inc. is set to discuss its second quarter 2025 financial results and business updates in a conference call scheduled for August 7, 2025 [1][2] Company Overview - Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [3] - The company is working on next-generation molecules that modulate G-protein coupled receptors, aiming to create first-in-class therapeutics with clinical and commercial differentiation [3] Clinical Trials - Skye is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, specifically targeting obesity [3] - The trial is also evaluating the combination of nimacimab with a GLP-1R agonist (Wegovy®) [3]